Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Mutations of the gene FNIP1 associated with a syndromic autosomal recessive immunodeficiency with cardiomyopathy and pre-excitation syndrome.

Niehues T, Özgür TT, Bickes M, Waldmann R, Schöning J, Bräsen J, Hagel C, Ballmaier M, Klusmann JH, Niedermayer A, Pannicke U, Enders A, Dückers G, Siepermann K, Hempel J, Schwarz K, Viemann D.

Eur J Immunol. 2020 Mar 17. doi: 10.1002/eji.201948504. [Epub ahead of print] No abstract available.

PMID:
32181500
2.

Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation.

Lukes J Jr, Danek P, Alejo-Valle O, Potuckova E, Gahura O, Heckl D, Starkova J, Stary J, Mejstrikova E, Alberich-Jorda M, Zuna J, Trka J, Klusmann JH, Zaliova M.

Leukemia. 2020 Feb 24. doi: 10.1038/s41375-020-0769-1. [Epub ahead of print] No abstract available.

PMID:
32094462
3.

The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia.

Grasedieck S, Ruess C, Krowiorz K, Lux S, Pochert N, Schwarzer A, Klusmann JH, Jongen-Lavrencic M, Herold T, Bullinger L, Pollack JR, Rouhi A, Kuchenbauer F.

Haematologica. 2020 Jan 2. pii: haematol.2019.235291. doi: 10.3324/haematol.2019.235291. [Epub ahead of print] No abstract available.

4.

The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.

Al-Kershi S, Bhayadia R, Ng M, Verboon L, Emmrich S, Gack L, Schwarzer A, Strowig T, Heckl D, Klusmann JH.

Blood Adv. 2019 Dec 23;3(24):4252-4263. doi: 10.1182/bloodadvances.2019032029.

5.

Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.

Pötschke R, Gielen G, Pietsch T, Kramm C, Klusmann JH, Hüttelmaier S, Kühnöl CD.

Pediatr Res. 2020 Mar;87(4):669-676. doi: 10.1038/s41390-019-0628-9. Epub 2019 Nov 22.

PMID:
31756732
6.

Molecular Approaches to Treating Pediatric Leukemias.

Kuhlen M, Klusmann JH, Hoell JI.

Front Pediatr. 2019 Sep 6;7:368. doi: 10.3389/fped.2019.00368. eCollection 2019. Review.

7.

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub JW, Crispino JD, Weiss MJ, Hayashi Y, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu SN, Vyas P, Heckl D, Klusmann JH.

Cancer Cell. 2019 Sep 16;36(3):340. doi: 10.1016/j.ccell.2019.08.014. No abstract available.

PMID:
31526763
8.

The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia.

Ng M, Heckl D, Klusmann JH.

Front Oncol. 2019 Jul 9;9:570. doi: 10.3389/fonc.2019.00570. eCollection 2019. Review.

9.

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub JW, Crispino JD, Weiss MJ, Hayashi Y, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu SN, Vyas P, Heckl D, Klusmann JH.

Cancer Cell. 2019 Aug 12;36(2):123-138.e10. doi: 10.1016/j.ccell.2019.06.007. Epub 2019 Jul 11. Erratum in: Cancer Cell. 2019 Sep 16;36(3):340.

PMID:
31303423
10.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. doi: 10.1016/j.bbmt.2019.01.016. Epub 2019 Jan 15. Review.

PMID:
30658222
11.

Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood.

Weihrauch-Blüher S, Schwarz P, Klusmann JH.

Metabolism. 2019 Mar;92:147-152. doi: 10.1016/j.metabol.2018.12.001. Epub 2018 Dec 5. Review.

PMID:
30529454
12.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

Flasinski M, Scheibke K, Zimmermann M, Creutzig U, Reinhardt K, Verwer F, de Haas V, van der Velden VHJ, von Neuhoff C, Zwaan CM, Reinhardt D, Klusmann JH.

Blood Adv. 2018 Jul 10;2(13):1532-1540. doi: 10.1182/bloodadvances.2018018945.

13.

GATA1s exerts developmental stage-specific effects in human hematopoiesis.

Gialesaki S, Mahnken AK, Schmid L, Labuhn M, Bhayadia R, Heckl D, Klusmann JH.

Haematologica. 2018 Aug;103(8):e336-e340. doi: 10.3324/haematol.2018.191338. Epub 2018 Mar 22. No abstract available.

14.

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.

Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, Lehrnbecher T, Creutzig U, Klusmann JH, Reinhardt D.

Leukemia. 2018 Oct;32(10):2167-2177. doi: 10.1038/s41375-018-0071-7. Epub 2018 Feb 22.

15.

Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.

Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, Fiedler J, Schwarzer A, Rouhi A, Heuser M, Wingert S, Bothur S, Döhner K, Mätzig T, Ng M, Reinhardt D, Döhner H, Zwaan CM, van den Heuvel Eibrink M, Heckl D, Fornerod M, Thum T, Humphries RK, Rieger MA, Kuchenbauer F, Klusmann JH.

J Clin Oncol. 2018 Apr 1;36(10):1007-1016. doi: 10.1200/JCO.2017.75.2204. Epub 2018 Feb 12.

PMID:
29432078
16.

Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells.

Pittermann E, Lachmann N, MacLean G, Emmrich S, Ackermann M, Göhring G, Schlegelberger B, Welte K, Schambach A, Heckl D, Orkin SH, Cantz T, Klusmann JH.

Blood Adv. 2017 Jun 2;1(14):903-914. doi: 10.1182/bloodadvances.2016003798. eCollection 2017 Jun 13.

17.

Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications.

Labuhn M, Adams FF, Ng M, Knoess S, Schambach A, Charpentier EM, Schwarzer A, Mateo JL, Klusmann JH, Heckl D.

Nucleic Acids Res. 2018 Feb 16;46(3):1375-1385. doi: 10.1093/nar/gkx1268.

18.

lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling.

Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, Singh B, Franklin JL, Wang J, Hu H, Wei T, Yang M, Yeatman TJ, Lee E, Saito-Diaz K, Hinger S, Patton JG, Chung CH, Emmrich S, Klusmann JH, Fan D, Coffey RJ.

Nat Med. 2017 Nov;23(11):1331-1341. doi: 10.1038/nm.4424. Epub 2017 Oct 16.

19.

The non-coding RNA landscape of human hematopoiesis and leukemia.

Schwarzer A, Emmrich S, Schmidt F, Beck D, Ng M, Reimer C, Adams FF, Grasedieck S, Witte D, Käbler S, Wong JWH, Shah A, Huang Y, Jammal R, Maroz A, Jongen-Lavrencic M, Schambach A, Kuchenbauer F, Pimanda JE, Reinhardt D, Heckl D, Klusmann JH.

Nat Commun. 2017 Aug 9;8(1):218. doi: 10.1038/s41467-017-00212-4.

20.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
21.

CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.

Reimer J, Knöß S, Labuhn M, Charpentier EM, Göhring G, Schlegelberger B, Klusmann JH, Heckl D.

Haematologica. 2017 Sep;102(9):1558-1566. doi: 10.3324/haematol.2017.164046. Epub 2017 Jun 1.

22.

Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.

Xie Y, Koch ML, Zhang X, Hamblen MJ, Godinho FJ, Fujiwara Y, Xie H, Klusmann JH, Orkin SH, Li Z.

Stem Cells. 2017 Jul;35(7):1773-1785. doi: 10.1002/stem.2627. Epub 2017 Apr 24.

23.

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.

Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, Scheffers L, Hasle H, Zwaan CM, Reinhardt D, Klusmann JH.

Blood. 2017 Jun 22;129(25):3314-3321. doi: 10.1182/blood-2017-01-765057. Epub 2017 Apr 11.

PMID:
28400376
24.

Classification of pediatric acute myeloid leukemia based on miRNA expression profiles.

Obulkasim A, Katsman-Kuipers JE, Verboon L, Sanders M, Touw I, Jongen-Lavrencic M, Pieters R, Klusmann JH, Michel Zwaan C, van den Heuvel-Eibrink MM, Fornerod M.

Oncotarget. 2017 May 16;8(20):33078-33085. doi: 10.18632/oncotarget.16525.

25.

Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jürgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wößmann W, Nathrath M, Bielack SS, Frühwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O.

Eur J Cancer. 2016 Sep;65:91-101. doi: 10.1016/j.ejca.2016.06.009. Epub 2016 Jul 29.

PMID:
27479119
26.

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.

Verboon LJ, Obulkasim A, de Rooij JD, Katsman-Kuipers JE, Sonneveld E, Baruchel A, Trka J, Reinhardt D, Pieters R, Cloos J, Kaspers GJ, Klusmann JH, Zwaan CM, Fornerod M, van den Heuvel-Eibrink MM.

Oncotarget. 2016 Jul 26;7(30):48412-48422. doi: 10.18632/oncotarget.10270.

27.

MicroRNA-125b-5p mimic inhibits acute liver failure.

Yang D, Yuan Q, Balakrishnan A, Bantel H, Klusmann JH, Manns MP, Ott M, Cantz T, Sharma AD.

Nat Commun. 2016 Jun 23;7:11916. doi: 10.1038/ncomms11916.

28.

Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome.

Scheer C, Kratz C, Witt O, Creutzig U, Reinhardt D, Klusmann JH.

Pediatr Blood Cancer. 2016 Sep;63(9):1677-9. doi: 10.1002/pbc.26062. Epub 2016 May 18.

PMID:
27191354
29.

Lost in translation: pluripotent stem cell-derived hematopoiesis.

Ackermann M, Liebhaber S, Klusmann JH, Lachmann N.

EMBO Mol Med. 2015 Nov;7(11):1388-402. doi: 10.15252/emmm.201505301. Review.

30.

miR-139-5p controls translation in myeloid leukemia through EIF4G2.

Emmrich S, Engeland F, El-Khatib M, Henke K, Obulkasim A, Schöning J, Katsman-Kuipers JE, Michel Zwaan C, Pich A, Stary J, Baruchel A, de Haas V, Reinhardt D, Fornerod M, van den Heuvel-Eibrink MM, Klusmann JH.

Oncogene. 2016 Apr 7;35(14):1822-31. doi: 10.1038/onc.2015.247. Epub 2015 Jul 13.

PMID:
26165837
31.

Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.

Schweitzer J, Zimmermann M, Rasche M, von Neuhoff C, Creutzig U, Dworzak M, Reinhardt D, Klusmann JH.

Ann Hematol. 2015 Aug;94(8):1327-36. doi: 10.1007/s00277-015-2383-2. Epub 2015 Apr 28.

32.

LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia.

Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH.

Mol Cancer. 2014 Jul 15;13:171. doi: 10.1186/1476-4598-13-171.

33.

miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling.

Emmrich S, Rasche M, Schöning J, Reimer C, Keihani S, Maroz A, Xie Y, Li Z, Schambach A, Reinhardt D, Klusmann JH.

Genes Dev. 2014 Apr 15;28(8):858-74. doi: 10.1101/gad.233791.113.

34.

GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.

Maroz A, Stachorski L, Emmrich S, Reinhardt K, Xu J, Shao Z, Käbler S, Dertmann T, Hitzler J, Roberts I, Vyas P, Juban G, Hennig C, Hansen G, Li Z, Orkin S, Reinhardt D, Klusmann JH.

Leukemia. 2014 Jun;28(6):1259-70. doi: 10.1038/leu.2013.373. Epub 2013 Dec 13.

35.

miR-9 is a tumor suppressor in pediatric AML with t(8;21).

Emmrich S, Katsman-Kuipers JE, Henke K, Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML, Verboon L, Stary J, Baruchel A, de Haas V, Danen-van Oorschot AA, Fornerod M, Pieters R, Reinhardt D, Klusmann JH, van den Heuvel-Eibrink MM.

Leukemia. 2014 May;28(5):1022-32. doi: 10.1038/leu.2013.357. Epub 2013 Nov 25.

PMID:
24270738
36.

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.

Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, Reinhardt D, Li Z, Orkin SH, Behrens GM, Klusmann JH.

Leukemia. 2014 Mar;28(3):577-88. doi: 10.1038/leu.2013.264. Epub 2013 Sep 12.

37.

[Long non-coding RNAs as central regulators of hematopoiesis and leukemogenesis].

Emmrich S, Klusmann JH.

Dtsch Med Wochenschr. 2013 Jun;138(24):1318-21. doi: 10.1055/s-0033-1343104. Epub 2013 Jun 4. Review. German. No abstract available.

PMID:
23737118
38.

Improved generation of patient-specific induced pluripotent stem cells using a chemically-defined and matrigel-based approach.

Groß B, Sgodda M, Rasche M, Schambach A, Göhring G, Schlegelberger B, Greber B, Linden T, Reinhardt D, Cantz T, Klusmann JH.

Curr Mol Med. 2013 Jun;13(5):765-76.

PMID:
23642058
39.

Prospects and challenges of reprogrammed cells in hematology and oncology.

Groß B, Pittermann E, Reinhardt D, Cantz T, Klusmann JH.

Pediatr Hematol Oncol. 2012 Sep;29(6):507-28. doi: 10.3109/08880018.2012.708707. Epub 2012 Aug 2. Review.

PMID:
22857266
40.

Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.

Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, Klusmann JH, Reinhardt D, Welte K.

Int J Cancer. 2013 Feb 15;132(4):766-74. doi: 10.1002/ijc.27726. Epub 2012 Aug 12.

41.

High frequency of copy number alterations in myeloid leukaemia of Down syndrome.

Blink M, van den Heuvel-Eibrink MM, Aalbers AM, Balgobind BV, Hollink IH, Meijerink JP, van der Velden VH, Beverloo BH, de Haas V, Hasle H, Reinhardt D, Klusmann JH, Pieters R, Calado RT, Zwaan CM.

Br J Haematol. 2012 Sep;158(6):800-3. doi: 10.1111/j.1365-2141.2012.09224.x. Epub 2012 Jul 7. No abstract available.

PMID:
22775985
42.

miRNAs can increase the efficiency of ex vivo platelet generation.

Emmrich S, Henke K, Hegermann J, Ochs M, Reinhardt D, Klusmann JH.

Ann Hematol. 2012 Nov;91(11):1673-84. doi: 10.1007/s00277-012-1517-z. Epub 2012 Jul 5.

PMID:
22763947
43.

Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.

Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, Selvakumar D, Klusmann JH, Reinhardt D, Welte K.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):371-7. doi: 10.1016/j.bbrc.2012.06.075. Epub 2012 Jun 21.

PMID:
22728882
44.

[GATA1-mutation associated leukemia in children with trisomy 21 mosaic].

Reinhardt D, Reinhardt K, Neuhoff C, Sander A, Klusmann JH, Pekrun A, Sauerbrey A, von Stackelberg A, Rössig C, Creutzig U, Kolenova A.

Klin Padiatr. 2012 Apr;224(3):153-5. doi: 10.1055/s-0032-1308988. Epub 2012 Apr 18. German.

PMID:
22513796
45.

Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease.

Blink M, van den Heuvel-Eibrink MM, de Haas V, Klusmann JH, Hasle H, Zwaan CM.

Haematologica. 2012 Apr;97(4):632-4. doi: 10.3324/haematol.2011.057505. No abstract available.

46.

Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.

Thol F, Kölking B, Damm F, Reinhardt K, Klusmann JH, Reinhardt D, von Neuhoff N, Brugman MH, Schlegelberger B, Suerbaum S, Krauter J, Ganser A, Heuser M.

Genes Chromosomes Cancer. 2012 Jul;51(7):689-95. doi: 10.1002/gcc.21955. Epub 2012 Mar 27.

PMID:
22454318
47.

The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T.

Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.

48.

Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.

Alford KA, Reinhardt K, Garnett C, Norton A, Böhmer K, von Neuhoff C, Kolenova A, Marchi E, Klusmann JH, Roberts I, Hasle H, Reinhardt D, Vyas P; International Myeloid Leukemia-Down Syndrome Study Group.

Blood. 2011 Aug 25;118(8):2222-38. doi: 10.1182/blood-2011-03-342774. Epub 2011 Jun 29.

PMID:
21715302
49.

DNMT3A mutations are rare in childhood acute myeloid leukemia.

Thol F, Heuser M, Damm F, Klusmann JH, Reinhardt K, Reinhardt D.

Haematologica. 2011 Aug;96(8):1238-40. doi: 10.3324/haematol.2011.046839. Epub 2011 Jun 17. No abstract available.

50.

Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.

Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, Zwaan CM, de Haas V, Creutzig U, Klusmann JH, Krauter J, Heuser M, Ganser A, Reinhardt D, Thiede C.

Leukemia. 2011 Nov;25(11):1704-10. doi: 10.1038/leu.2011.142. Epub 2011 Jun 7.

PMID:
21647152

Supplemental Content

Loading ...
Support Center